vs

Side-by-side financial comparison of CMB.TECH NV (CMBT) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

West Pharmaceutical Services is the larger business by last-quarter revenue ($805.0M vs $592.8M, roughly 1.4× CMB.TECH NV). CMB.TECH NV runs the higher net margin — 32.3% vs 16.4%, a 15.8% gap on every dollar of revenue. On growth, West Pharmaceutical Services posted the faster year-over-year revenue change (7.5% vs -34.6%).

CMB.TECH, before October 2024 known as Euronav, is a crude oil tanker transport company, which consists of VLCCs, Suezmaxes and FSOs.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

CMBT vs WST — Head-to-Head

Bigger by revenue
WST
WST
1.4× larger
WST
$805.0M
$592.8M
CMBT
Growing faster (revenue YoY)
WST
WST
+42.1% gap
WST
7.5%
-34.6%
CMBT
Higher net margin
CMBT
CMBT
15.8% more per $
CMBT
32.3%
16.4%
WST

Income Statement — Q4 FY2024 vs Q4 FY2025

Metric
CMBT
CMBT
WST
WST
Revenue
$592.8M
$805.0M
Net Profit
$191.2M
$132.1M
Gross Margin
37.8%
Operating Margin
46.4%
19.5%
Net Margin
32.3%
16.4%
Revenue YoY
-34.6%
7.5%
Net Profit YoY
-63.3%
1.5%
EPS (diluted)
$1.01
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMBT
CMBT
WST
WST
Q4 25
$805.0M
Q3 25
$804.6M
Q2 25
$766.5M
Q1 25
$698.0M
Q4 24
$592.8M
$748.8M
Q3 24
$746.9M
Q2 24
$702.1M
Q1 24
$695.4M
Net Profit
CMBT
CMBT
WST
WST
Q4 25
$132.1M
Q3 25
$140.0M
Q2 25
$131.8M
Q1 25
$89.8M
Q4 24
$191.2M
$130.1M
Q3 24
$136.0M
Q2 24
$111.3M
Q1 24
$115.3M
Gross Margin
CMBT
CMBT
WST
WST
Q4 25
37.8%
Q3 25
36.6%
Q2 25
35.7%
Q1 25
33.2%
Q4 24
36.5%
Q3 24
35.4%
Q2 24
32.8%
Q1 24
33.1%
Operating Margin
CMBT
CMBT
WST
WST
Q4 25
19.5%
Q3 25
20.8%
Q2 25
20.1%
Q1 25
15.3%
Q4 24
46.4%
21.3%
Q3 24
21.6%
Q2 24
18.0%
Q1 24
17.7%
Net Margin
CMBT
CMBT
WST
WST
Q4 25
16.4%
Q3 25
17.4%
Q2 25
17.2%
Q1 25
12.9%
Q4 24
32.3%
17.4%
Q3 24
18.2%
Q2 24
15.9%
Q1 24
16.6%
EPS (diluted)
CMBT
CMBT
WST
WST
Q4 25
$1.82
Q3 25
$1.92
Q2 25
$1.82
Q1 25
$1.23
Q4 24
$1.01
$1.78
Q3 24
$1.85
Q2 24
$1.51
Q1 24
$1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMBT
CMBT
WST
WST
Cash + ST InvestmentsLiquidity on hand
$38.9M
$791.3M
Total DebtLower is stronger
$2.6B
$202.8M
Stockholders' EquityBook value
$1.2B
$3.2B
Total Assets
$3.9B
$4.3B
Debt / EquityLower = less leverage
2.20×
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMBT
CMBT
WST
WST
Q4 25
$791.3M
Q3 25
$628.5M
Q2 25
$509.7M
Q1 25
$404.2M
Q4 24
$38.9M
$484.6M
Q3 24
$490.9M
Q2 24
$446.2M
Q1 24
$601.8M
Total Debt
CMBT
CMBT
WST
WST
Q4 25
$202.8M
Q3 25
$202.7M
Q2 25
$202.6M
Q1 25
$202.6M
Q4 24
$2.6B
$202.6M
Q3 24
$202.6M
Q2 24
$205.8M
Q1 24
$206.2M
Stockholders' Equity
CMBT
CMBT
WST
WST
Q4 25
$3.2B
Q3 25
$3.1B
Q2 25
$2.9B
Q1 25
$2.7B
Q4 24
$1.2B
$2.7B
Q3 24
$2.8B
Q2 24
$2.6B
Q1 24
$2.7B
Total Assets
CMBT
CMBT
WST
WST
Q4 25
$4.3B
Q3 25
$4.1B
Q2 25
$4.0B
Q1 25
$3.6B
Q4 24
$3.9B
$3.6B
Q3 24
$3.7B
Q2 24
$3.5B
Q1 24
$3.6B
Debt / Equity
CMBT
CMBT
WST
WST
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.08×
Q4 24
2.20×
0.08×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMBT
CMBT
WST
WST
Operating Cash FlowLast quarter
$204.4M
$251.1M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
21.7%
Capex IntensityCapex / Revenue
9.5%
Cash ConversionOCF / Net Profit
1.07×
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMBT
CMBT
WST
WST
Q4 25
$251.1M
Q3 25
$197.2M
Q2 25
$177.1M
Q1 25
$129.4M
Q4 24
$204.4M
$190.1M
Q3 24
$180.1M
Q2 24
$165.0M
Q1 24
$118.2M
Free Cash Flow
CMBT
CMBT
WST
WST
Q4 25
$175.0M
Q3 25
$133.9M
Q2 25
$101.9M
Q1 25
$58.1M
Q4 24
$85.2M
Q3 24
$98.8M
Q2 24
$64.8M
Q1 24
$27.6M
FCF Margin
CMBT
CMBT
WST
WST
Q4 25
21.7%
Q3 25
16.6%
Q2 25
13.3%
Q1 25
8.3%
Q4 24
11.4%
Q3 24
13.2%
Q2 24
9.2%
Q1 24
4.0%
Capex Intensity
CMBT
CMBT
WST
WST
Q4 25
9.5%
Q3 25
7.9%
Q2 25
9.8%
Q1 25
10.2%
Q4 24
14.0%
Q3 24
10.9%
Q2 24
14.3%
Q1 24
13.0%
Cash Conversion
CMBT
CMBT
WST
WST
Q4 25
1.90×
Q3 25
1.41×
Q2 25
1.34×
Q1 25
1.44×
Q4 24
1.07×
1.46×
Q3 24
1.32×
Q2 24
1.48×
Q1 24
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMBT
CMBT

Segment breakdown not available.

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons